Doug Langa - Novo Nordisk President
| NVO Stock | USD 127.66 0.81 0.64% |
President
Mr. Doug Langa was Executive Vice President, North America Operations at Novo Nordisk AS since August 15, 2017. He has previously been Senior Vice President, Head of North America Operations, President of Novo Nordisk Inc. at Novo Nordisk AS since March 1, 2017. He has previously been Senior Vice President for Market Access, Novo Nordisk Inc since 2016. He joined the company in 2011 as senior director, Managed Markets and in 2015 was appointed Corporationrationoate Vice President of Market Access in the US. He came from GlaxoSmithKline where he was senior director of Payer Marketing. Prior to GSK, Doug Langa spent the majority of his career at Johnson Johnson, where he held various roles of increasing responsibility within Managed Markets, Sales Leadership and Marketing. He has over 25 years of experience in the pharmaceutical and medical device industry. He graduated from Widener University and earned MBA from Fordham University. since 2017.
| Age | 52 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | Novo Alle 1, Bagsvaerd, Denmark, 2880 |
| Phone | 45 44 44 88 88 |
| Web | https://www.novonordisk.com |
Novo Nordisk Management Efficiency
The company has Return on Asset of 0.2339 % which means that on every $100 spent on assets, it made $0.2339 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8807 %, implying that it generated $0.8807 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 29th of April 2024, Return On Capital Employed is likely to grow to 0.74, while Return On Assets are likely to drop 0.14. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 29th of April 2024, Intangibles To Total Assets is likely to grow to 0.20, while Non Currrent Assets Other are likely to drop about 1.4 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Daniel Plew | Regeneron Pharmaceuticals | 51 | |
| Manmeet Soni | Alnylam Pharmaceuticals | 40 | |
| Susan Hensley | Novavax | N/A | |
| Ian Smith | Vertex Pharmaceuticals | 51 | |
| Masako Nakamura | Alnylam Pharmaceuticals | N/A | |
| Edward Kaye | Sarepta Therapeutics | 66 | |
| Joan Wood | Sarepta Therapeutics | N/A | |
| Alan Eisenberg | Alnylam Pharmaceuticals | N/A | |
| Marc Schneebaum | Madrigal Pharmaceuticals | 64 | |
| Louis Fries | Novavax | N/A | |
| Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
| Jing Marantz | Alnylam Pharmaceuticals | N/A | |
| Kevin Fitzgerald | Alnylam Pharmaceuticals | 55 | |
| John Gray | Vertex Pharmaceuticals | 53 | |
| Theresa Heggie | Alnylam Pharmaceuticals | 56 | |
| Peter Powchik | Regeneron Pharmaceuticals | 59 | |
| Yvonne Greenstreet | Alnylam Pharmaceuticals | 55 | |
| Christopher Fenimore | Regeneron Pharmaceuticals | 53 | |
| Kathleen Callahan | Novavax | N/A | |
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| Pushkal Garg | Alnylam Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 0.88 | ||||
| Return On Asset | 0.23 |
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Soeren Pedersen, Director, Employee Representative | ||
| Doug Langa, Senior Vice President Head of North America Operations and Presidentident of Novo Nordisk Inc. | ||
| Jakob Riis, Executive VP of China, Pacific and Marketing and Member of Executive Management | ||
| Kasim Kutay, Director | ||
| Jesper Brandgaard, CFO, Executive Vice President | ||
| Sylvie Gregoire, Independent Director | ||
| Mette Jensen, Director, Employee Representative | ||
| Mary Szela, Director | ||
| Jerzy Gruhn, Executive Vice President Europe | ||
| Douglas Langa, Executive Vice President - North America Operations | ||
| Eivind Kolding, Director | ||
| Kasper Poulsen, Head of Investor Relations, Corporate Vice President | ||
| Thomas Rantzau, Director, Employee Representative | ||
| Lars Jorgensen, CEO President | ||
| Daniel Bohsen, CVP Relations | ||
| Henrik Poulsen, Director | ||
| Karsten Knudsen, Chief Financial Officer, Executive Vice President | ||
| Lars Joergensen, President, Chief Executive Officer | ||
| Helge Lund, Independent Chairman of the Board | ||
| Martin Lange, Executive Vice President - Development | ||
| Maziar Doustdar, Executive Vice President - International Operations | ||
| Brian Daniels, Independent Director | ||
| Goran Ando, Chairman of the Board | ||
| Martin Mackay, Independent Director | ||
| Jeppe Christiansen, Vice Chairman of the Board | ||
| Bruno Angelici, Independent Director | ||
| Liselotte Hyveled, Director, Employee Representative | ||
| Anne Kverneland, Director, Employee Representative | ||
| Tania Sabroe, Executive Board | ||
| Kaare Schultz, President COO | ||
| Liz Hewitt, Independent Director | ||
| Jesper Hoeiland, Executive Vice President US | ||
| Ludovic Helfgott, Executive Vice President of Biopharm | ||
| Camilla Sylvest, Executive Vice President - Commercial Strategy and Corporate Affairs | ||
| Mads Thomsen, Chief Science Officer, Executive VP and Member of Executive Management | ||
| Andreas Fibig, Independent Director | ||
| Monique Carter, Executive Vice President - People and Organisation | ||
| Peter Ankersen, Corporate Vice President & Head of Investor Relations | ||
| Laurence Debroux, Independent Director | ||
| Lars Soerensen, CEO | ||
| Marcus Schindler, Executive Vice President - Research and Early Development, Chief Scientific Officer | ||
| Stig Stroebaek, Director, Employee Representative | ||
| Henrik Wulff, Executive Vice President - Product Supply Quality and IT | ||
| Thomas Koestler, Independent Director | ||
| Lars Green, Executive Vice President Business Services & Compliance |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.88 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 562.31 B | ||||
| Shares Outstanding | 4.46 B | ||||
| Shares Owned By Institutions | 9.34 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 36.21 X |
Novo Nordisk Investors Sentiment
The influence of Novo Nordisk's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novo Nordisk's public news can be used to forecast risks associated with an investment in Novo. The trend in average sentiment can be used to explain how an investor holding Novo can time the market purely based on public headlines and social activities around Novo Nordisk AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novo Nordisk's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novo Nordisk's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novo Nordisk's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novo Nordisk.
Novo Nordisk Implied Volatility | 57.55 |
Novo Nordisk's implied volatility exposes the market's sentiment of Novo Nordisk AS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novo Nordisk's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novo Nordisk stock will not fluctuate a lot when Novo Nordisk's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.631 | Dividend Share 9.4 | Earnings Share 2.68 | Revenue Per Share 51.812 | Quarterly Revenue Growth 0.37 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.